



# Essentials of Pediatric Hematology/ Oncology Nursing

**A CORE CURRICULUM**  
**FOURTH EDITION**

**EDITOR**

Nancy E. Kline

**SECTION EDITORS**

Rosalind Bryant

Claire A. Carlson

Mary C. Hooke

Colleen Nixon

**APHON**

ASSOCIATION of PEDIATRIC  
HEMATOLOGY/ONCOLOGY NURSES

---

## Contents

<b>Acknowledgments</b> .....	xi
<b>Contributors</b> .....	xiii
<b>Section 1. Pediatric Hematology/Oncology Nursing Practice</b>	
History and Philosophy of Pediatric Oncology Nursing .....	2
<i>Mary C. Hooke and Marilyn J. Hockenberry</i>	
Standards of Pediatric Oncology Nursing .....	5
<i>Joan O'Hanlon Curry and Revonda B. Mosher</i>	
Association of Pediatric Hematology/Oncology Nurses .....	9
<i>Melody Ann Watral</i>	
<b>Section 2. Pediatric Cancers</b>	
Overview of Childhood Cancer .....	14
<i>Christina Baggott</i>	
Epidemiology of Childhood Cancer .....	15
<i>Kathy Ruccione</i>	
Leukemia .....	25
<i>Kathy McCarthy</i>	
Non-Hodgkin Lymphoma .....	32
<i>Meredith Lahl</i>	
Hodgkin Lymphoma .....	39
<i>Meredith Lahl</i>	
Central Nervous System Tumors .....	44
<i>Melody Ann Watral</i>	
Neuroblastoma .....	50
<i>Linda D'Andrea</i>	
Osteosarcoma .....	58
<i>Judith Ann Holloway and Joan O'Hanlon Curry</i>	
Ewing Sarcoma of Bone and Soft Tissue and Peripheral Primitive Neuroectodermal Tumors .....	63
<i>Rebecca D'Amore and Joan O'Hanlon Curry</i>	
Tumors of the Kidney .....	67
<i>Mary Cogan</i>	
Rhabdomyosarcoma .....	73
<i>Julie McMahan</i>	
Retinoblastoma .....	78
<i>Maura Murphy Abbott</i>	
Rare Tumors of Childhood .....	82
<i>Maura Murphy Abbott</i>	
Bibliography .....	86

**Section 3. Overview of Hematology**

Origin of Blood Cells. . . . . 90  
*Christina Baggott*  
 Anemia. . . . . 92  
*Christina Baggott*  
 Neutropenia. . . . . 95  
*Christina Baggott*  
 Thrombocytopenia. . . . . 97  
*Christina Baggott*  
 Bibliography. . . . . 99

**Section 4. Childhood Cancer Treatment**

Diagnostic and Staging Procedures . . . . . 102  
*Ijeoma Julie Eche*  
 History of Chemotherapy . . . . . 106  
*Christine Sullivan*  
 Clinical Trials. . . . . 109  
*Elizabeth A. Gilger*  
 Chemotherapy . . . . . 111  
*Cailin Toomey*  
 Guidelines for the Safe Handling of Chemotherapy . . . . . 140  
*Susanne Brewster Conley*  
 Administration of Vesicants. . . . . 142  
*Mary Lynn Rae and Linda Madsen*  
 Surgery. . . . . 147  
*Carol Rossetto*  
 Radiation Therapy . . . . . 151  
*Joy Hesselgrave and Christine Chordas*  
 Hematopoietic Stem-Cell Transplantation . . . . . 160  
*Robbie Norville and Sharon Staton*  
 Biologic Response Modifiers . . . . . 180  
*Colleen Hill Dansereau*  
 Cell and Gene Therapy . . . . . 186  
*Robbie Norville*  
 Complementary and Alternative Treatments. . . . . 193  
*Laura Freedman*  
 Bibliography. . . . . 196

**Section 5. Side Effects of Treatment**

Bone-Marrow Suppression . . . . . 200  
*Nan Werther*

## Contents

---

Impairment of the Immune System.....	203
<i>Lisa Morrissey</i>	
Central Nervous System Complications .....	207
<i>Tara Kelly</i>	
Ototoxicity.....	215
<i>Kathryn Matson</i>	
Endocrine Abnormalities.....	217
<i>Rebecca A. Monroe</i>	
Cardiac and Pulmonary Complications.....	219
<i>Barbara Cuccovia</i>	
Gastrointestinal Complications.....	221
<i>Joan O'Hanlon Curry and Colleen Nixon</i>	
Renal and Bladder Complications .....	232
<i>Maura Padula</i>	
Skin Changes.....	234
<i>Caroline Costello</i>	
Musculoskeletal Complications.....	237
<i>Sameeya Ahmed-Winston</i>	
Nutritional Complications.....	239
<i>Tonya L. Bauer</i>	
Growth and Developmental Complications .....	241
<i>Maritza Salazar-Abshire</i>	
Pain .....	244
<i>Eufemia Jacob</i>	
Oncologic Emergencies.....	252
<i>Rita Secola and Debbie Reid</i>	
Bibliography.....	259
<b>Section 6. Supportive Care</b>	
Psychological Preparation and Support for Painful Procedures .....	264
<i>Catherine Fiona Macpherson</i>	
Sedation for Painful Procedures.....	267
<i>Catherine Fiona Macpherson</i>	
Central Venous Access Devices .....	269
<i>Kathleen Adlard</i>	
Nutritional Support .....	275
<i>Nancy E. Kline</i>	
Treatment of Infections .....	281
<i>Pat Wills Bagnato</i>	

Blood Product Support .....	289
<i>Teresa Conte</i>	
Bibliography.....	294
<b>Section 7. Psychosocial Issues</b>	
Development in Children with Cancer and Blood Disorders: Introduction .....	298
<i>Mary C. Hooke</i>	
Development of Infants (Birth–1 Year) .....	299
<i>Mary C. Hooke</i>	
Development of Toddlers (1–3 Years) .....	300
<i>Mary C. Hooke</i>	
Development of Preschoolers (4–6 Years) .....	302
<i>Mary C. Hooke</i>	
Development of School-Age Children (7–12 Years) .....	304
<i>Linda Madsen</i>	
Development of Adolescents (13–17 Years).....	307
<i>Linda Madsen</i>	
Development of Young Adults (18–25 Years) .....	312
<i>Mary C. Hooke and Linda Madsen</i>	
Care of Families .....	317
<i>Katherine Patterson Kelly</i>	
Cross-Cultural Care and Competence.....	327
<i>Stephanie Gil</i>	
Spirituality .....	332
<i>Susan O’Conner-Von</i>	
School Reentry and Attendance .....	333
<i>Kendal Jackson Temple</i>	
Professional Nurse-Patient Relationships .....	338
<i>Terri Boyce</i>	
Bibliography.....	344
<b>Section 8. Patient and Family Education</b>	
Teaching According to Developmental Level .....	348
<i>Kristen Graham</i>	
Family Education.....	353
<i>Sara Mosadegh</i>	
Critical Teaching-Learning Periods.....	356
<i>Sara Mosadegh</i>	
The Pediatric Hematology/Oncology Nurse as Educator .....	361
<i>Sara Mosadegh</i>	
Bibliography.....	363

### Section 9. Care of the Terminally Ill Child and the Family

Children and Death . . . . .	366
<i>Angela M. Ethier</i>	
Physical Care of the Terminally Ill Child . . . . .	368
<i>Janice Nuubiwa</i>	
Psychosocial Care of the Terminally Ill Child . . . . .	374
<i>Janice Nuubiwa</i>	
Bereavement . . . . .	377
<i>Rebecca A. Monroe</i>	
Professionals' Grief, Distress, and Bereavement . . . . .	380
<i>Cynthia Stutzer</i>	
Moral Distress . . . . .	383
<i>Cynthia Stutzer</i>	
Ethical Dilemmas in Terminal Care . . . . .	385
<i>Kristin Stegenga</i>	
Legal Concerns in Terminal Care . . . . .	388
<i>Kristin Stegenga</i>	
Bibliography . . . . .	389

### Section 10. Late Effects of Childhood Cancer

Definition and Overview . . . . .	392
<i>Wendy Hobbie and Claire A. Carlson</i>	
Central Nervous System . . . . .	405
<i>Joanne Quillen</i>	
Hypothalamic-Pituitary Axis . . . . .	407
<i>Deborah Diotallevi and Elaine Pottenger</i>	
Thyroid Function . . . . .	411
<i>Deborah Diotallevi and Elaine Pottenger</i>	
Vision and Hearing . . . . .	413
<i>Debra Eshelman-Kent</i>	
Head and Neck . . . . .	416
<i>Maureen M. Reilly and Claire A. Carlson</i>	
Cardiovascular System . . . . .	419
<i>Joanne Quillen</i>	
Respiratory System . . . . .	421
<i>Claire A. Carlson and Maureen M. Reilly</i>	
Gastrointestinal and Hepatic Systems . . . . .	423
<i>Claire A. Carlson and Maureen M. Reilly</i>	
Genitourinary System . . . . .	427
<i>Debra Eshelman-Kent</i>	

Reproductive System: Testes .....	430
<i>Sue Ogle and Wendy Hobbie</i>	
Reproductive System: Ovaries .....	432
<i>Sue Ogle and Wendy Hobbie</i>	
Musculoskeletal System .....	434
<i>Debra Eshelman-Kent</i>	
Hematopoietic System .....	437
<i>Claire A. Carlson and Jill Brace O'Neill</i>	
Immune System .....	438
<i>Claire A. Carlson and Jill Brace O'Neill</i>	
Second Neoplasms .....	440
<i>Elizabeth Whittam</i>	
Psychosocial Effects: Personal and Emotional .....	443
<i>Lisa Schwartz, Lauren Daniel, Matthew Hocking, and Branlyn DeRosa</i>	
Psychosocial Effects: Employment and Insurance .....	445
<i>Lauren Daniel, Matthew Hocking, and Lisa Schwartz</i>	
Psychosocial Effects: Educational Issues .....	448
<i>Matthew Hocking, Branlyn DeRosa, Lauren Daniel, and Lisa Schwartz</i>	
Promoting Health After Childhood Cancer .....	450
<i>Roseann Tucci</i>	
Bibliography .....	451
<b>Section 11. Hematology</b>	
Autoimmune Hemolytic Anemia .....	460
<i>Karyn Brundige</i>	
Sickle-Cell Disease .....	463
<i>Rosalind Bryant</i>	
Thalassemia .....	468
<i>Rosalind Bryant</i>	
Glucose-6-Phosphate Dehydrogenase Deficiency .....	472
<i>Deborah Robinson</i>	
Hereditary Spherocytosis .....	474
<i>Susanne Rosenberg</i>	
Bone-Marrow-Failure Syndromes .....	476
<i>Joan O'Brien Shea</i>	
Shwachman-Diamond Syndrome .....	484
<i>Teresa Conte</i>	
Chronic Neutropenia .....	486
<i>Karyn Brundige</i>	

## Contents

---

Immune Thrombocytopenic Purpura .....	492
<i>Susanne Rosenberg</i>	
Evans Syndrome .....	494
<i>Karyn Brundige</i>	
Thrombosis and Thrombophilia .....	498
<i>Kathy Harney</i>	
Hemolytic-Uremic Syndrome .....	501
<i>Leticia Valdiviez</i>	
Paroxysmal Nocturnal Hemoglobinuria.....	506
<i>Colleen Nixon</i>	
Hemophilia .....	510
<i>Teresa Gonte</i>	
Von Willebrand Disease .....	516
<i>Nancy E. Kline</i>	
Bibliography.....	521
<b>Index</b> .....	525



## Bone-Marrow Suppression

Nan Werther

Bone-marrow suppression results from an insult to normal functioning bone marrow, whether from disease or induced by chemotherapy or radiation. Suppression of the marrow leads to a decline in the hematopoietic stem-cell line of red blood cells (RBCs), white blood cells, and platelets. After myelosuppressive therapy, bone-marrow suppression can be noted within 10 to 14 days, with its lowest point identified as the nadir. The timing of the recovery of blood counts is affected by the treatment the patient receives as well as by the patient's history of previous therapies. During blood count recovery, the patient remains at risk for serious infection and bleeding. Administration of blood products and colony-stimulating factors (CSFs) (i.e., granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], Epogen) provides protection and assists in the recovery of the blood counts for the patient.

### Conditions Related to Bone-Marrow Suppression

#### Anemia

##### Definition

*Anemia* is a deficiency in the number of RBCs necessary for normal tissue and organ oxygenation due to hemolysis, replacement of bone marrow by malignant cells, myelosuppression induced by chemotherapy or radiation, viral suppression, or the effects of a chronic disease.

##### Clinical Presentation

The symptoms of anemia include fatigue; pale skin, lips, and nail beds; tachycardia; tachypnea; decreased energy; and headache.

No evidence-based guidelines currently exist for determining when to transfuse a pediatric patient with RBCs; therefore, it is important to understand that laboratory values guide clinical decisions, and it is necessary to base transfusions on patient needs (Agrawal, Hastings, & Feusner, 2010) (**Table 5-1**).

##### Treatment

All pediatric RBCs must be leukocyte depleted and irradiated. Dosing for pediatric patients is 10–15 ml/kg over 2–4 hours, completed within 4 hours. Volume is based on ml/kg of the patient's body weight, with the

**Table 5-1. Disease and Treatment Transfusion: Suggested Guidelines Based on Hemoglobin**

Indication	Hemoglobin
Prior to a course of chemotherapy	<8 g/dl
Receiving radiation therapy (controversial)	8–10 g/dl
Recovering from therapy-induced bone-marrow suppression; asymptomatic	<7 g/dl
Signs and symptoms of anemia	<7–8 g/dl
Active bleeding or procedure with anticipated blood loss	<8–10 g/dl

*Note.* Adapted from “Hematological Supportive Care for Children with Cancer,” by A. K. Agrawal, C. A. Hastings, and J. Feusner, 2010, in P. A. Pizzo and D. G. Poplack (Eds.), *Principles and Practice of Pediatric Oncology* (6th ed., pp. 1152–1189), Philadelphia, PA: Lippincott Williams and Wilkins; “Blood Transfusion Therapy,” by C. Nixon, 2010, in D. Tomlinson and N. E. Kline (Eds.), *Pediatric Oncology Nursing: Advanced Clinical Handbook* (2nd ed., pp. 546–557), Berlin, Germany: Springer-Verlag.

standard being 10 ml/kg (Agrawal et al., 2010). The hemoglobin should increase by 2–3 g/dl. Adult dosing is 1–2 units over 2–4 hours, completed within 4 hours. Packed RBCs must be ABO compatible (**Table 5-2**), based on patients' ABO typing (American Red Cross, 2013).

Stimulation of erythropoiesis with EPO-stimulating agents (ESAs) such as erythropoietin (Epogen) should be considered, particularly for patients whose cultural and religious beliefs prevent them from receiving transfusions. Patients and families need to understand that guidelines on the use of ESAs and their safety and effectiveness are limited and have not been established in pediatric patients with cancer. In adult patients, such hematopoietic CSFs have been shown to decrease the need for red-cell transfusions, as well as improve the quality of life, particularly in patients who experience fatigue related to anemia (Agrawal et al., 2010).

#### Thrombocytopenia

##### Definition

*Thrombocytopenia* is a deficiency in the number of platelets necessary for blood clotting caused by

## Section 5. Side Effects of Treatment

**Table 5-2. ABO Compatibility**

Patient with ABO Blood Type	Can Donate Red Cells to	Can Receive Red Cells from
O+	O+, A+, B+, AB+	O+, O-
O-	All types (universal donor)	O-
A+	A+, B+	A+, A-, O+, O-
A-	A-, A+, AB-, AB+	A-, O-
B+	B+, AB+	B+, B-, O+, O-
B-	B-, B+, AB-, AB+	B-, O-
AB+	AB+	All types Universal recipient
AB-	AB-, AB+	AB-, A-, B-, O-

myelosuppressive therapy, malignant cells in the bone marrow, increased consumption of platelets (i.e., disseminated intravascular coagulation), or fever.

### Clinical Presentation

Thrombocytopenia presents with petechiae, increased bruising, epistaxis, mucosal bleeding, hematuria, hematochezia, neurological changes secondary to intracranial bleeding, and spontaneous bleeding if platelet count is lower than 5,000/mm<sup>3</sup>.

### Laboratory Findings

- Mild thrombocytopenia: platelet count of 75,000/mm<sup>3</sup> to 99,999/mm<sup>3</sup>
- Moderate thrombocytopenia: platelet count of 50,000/mm<sup>3</sup> to 74,900/mm<sup>3</sup>
- Moderately severe thrombocytopenia: platelet count of 20,000 to 49,900/mm<sup>3</sup>
- Severe thrombocytopenia: platelet count of <20,000/mm<sup>3</sup>

### Treatment

Maintain platelet count of >10,000/mm<sup>3</sup> by administering single-donor, irradiated, cytomegalovirus-negative, leukocyte-depleted platelets. The advantages of

providing single-donor platelets are (a) it decreases donor exposure by using platelets obtained by the apheresis technology, (b) it reduces the potential transfusion-transmitted infections, and (c) it decreases the incidence of alloimmunization (Slichter, 2007). The number of units of platelets ordered for a patient is based on the weight of the child and the desired post-transfusion platelet count. A dose of 1 unit per 10 kg of single-donor platelets should increase the platelet count by 50,000–100,000 platelets/mm<sup>3</sup> by 1 hour posttransfusion (Agrawal et al., 2010). Consider maintaining a platelet count of >50,000/mm<sup>3</sup> for patients with signs of bleeding, high fever, hyperleukocytosis, a rapid decrease in platelet count, or coagulation abnormalities and for those undergoing invasive procedures such as lumbar punctures, bone marrow aspirations and biopsies, surgeries, or endotracheal intubation. The administration of oprelvekin (Neumega, IL-11)—a thrombopoietic growth factor that stimulates proliferation and maturation of megakaryocytes in the bone marrow, resulting in an increased number of circulating platelets—is controversial. Its safety and efficacy have not been established in pediatric patients, particularly those younger than 12 years of age (Children's Oncology Group [COG], 2009). Platelet transfusion guidelines are summarized in **Table 5-3**.

## Neutropenia

### Definition

*Neutropenia* is a reduction in circulating neutrophils or white blood cells that is determined by the percentage of segmented neutrophils and band neutrophils that constitute the total white blood cell (WBC) count. Neutropenia is the most severe consequence of bone-marrow suppression. The risk of infection is determined by the absolute neutrophil count (ANC). ANC is calculated as total WBCs × neutrophils (i.e., % polys + % bands).

### Clinical Presentation

Neutropenia can be asymptomatic; however, if a patient is anemic or thrombocytopenic, he or she frequently is also neutropenic. The symptoms associated with neutropenia include fever and infection (bacterial, fungal, viral).

### Severity of Neutropenia

- Mild: ANC of 1,500–1,900/mm<sup>3</sup>
- Moderate: ANC of 1,000–1,499/mm<sup>3</sup>